Preclinical trials demonstrated that ibrutinib promotes apoptosis of CLL cells, inhibits activation of phosphatidylinositol‐3 kinase (PI3K), ERK1, and NF‐κB by external microenvironment signals, and also prevents CLL proliferation.6 The gene discussed is MAPK3; the disease is B-cell chronic lymphocytic leukemia.